

---

## Product Datasheet

### CCR4 antibody (orb1152504)

Evolution Biocomponents.  
**Description**

Mouse monoclonal antibody to CCR4

<b>Species/Host</b>	Human
<b>Reactivity</b>	Human
<b>Conjugation</b>	Unconjugated
<b>Tested Applications</b>	Depletion
<b>Immunogen</b>	This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
<b>Target</b>	CCR4
<b>Preservatives</b>	PBS with 0.02% Proclin 300.
<b>Concentration</b>	1 mg/ml
<b>Storage</b>	Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
<b>Note</b>	For research use only
<b>Application notes</b>	<p>The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8% and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action; in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Biorbyt has not been de-fucosylated.</p>
<b>Isotype</b>	IgG2a
<b>Clonality</b>	Monoclonal